富国恒生港股通创新药及医疗保健ETF发起式联接C(020111)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-140,037,927.51 |
118,048,596.45 |
118,950,157.89 |
-1,596,750.85 |
| 利息合计 |
144,617.09 |
349,039.08 |
105,175.24 |
15,878.24 |
| 其中：存款利息收入 |
144,617.09 |
349,039.08 |
105,175.24 |
15,878.24 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-21,951,864.85 |
156,698,059.26 |
41,982,497.14 |
-1,097,700.16 |
| 其中：股票投资收益 |
- |
- |
- |
- |
| 基金投资收益 |
-22,272,410.21 |
156,254,357.03 |
41,884,645.47 |
-1,116,752.55 |
| 债券投资收益 |
320,545.36 |
443,702.23 |
97,851.67 |
19,052.39 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
- |
- |
- |
- |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-118,697,839.90 |
-40,516,191.55 |
76,284,863.94 |
-537,231.33 |
| 其他收入 |
467,160.15 |
1,517,689.66 |
577,621.57 |
22,302.40 |
| 费用 |
1,025,765.94 |
2,054,467.20 |
581,196.78 |
49,942.83 |
| 管理人报酬 |
64,738.11 |
131,620.76 |
41,517.81 |
5,878.54 |
| 基金托管费 |
12,947.61 |
26,324.16 |
8,303.58 |
1,175.70 |
| 销售服务费 |
591,937.73 |
835,221.08 |
231,885.48 |
13,911.34 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
266,425.78 |
395,531.55 |
112,194.90 |
15,977.25 |
| 其中：卖出回购金融资产支出 |
266,425.78 |
395,531.55 |
112,194.90 |
15,977.25 |
| 其他费用 |
81,323.61 |
103,000.00 |
36,447.22 |
13,000.00 |
| 利润总额 |
-141,063,693.45 |
115,994,129.25 |
118,368,961.11 |
-1,646,693.68 |
微信公众号
证券之星APP
基本资料
